GALECTIN-8 Is a Neuroprotective Factor in the Brain that Can Be Neutralized by Human Autoantibodies.

Evelyn Pardo, Francisca Barake, Juan A Godoy, Claudia Oyanadel, Sofía Espinoza, Claudia Metz, Claudio Retamal, Loreto Massardo, Cheril Tapia-Rojas, Nibaldo C Inestrosa, Andrea Soza, Alfonso González
Author Information
  1. Evelyn Pardo: Centro de Envejecimiento y Regeneración (CARE), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
  2. Francisca Barake: Centro de Envejecimiento y Regeneración (CARE), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
  3. Juan A Godoy: Centro de Envejecimiento y Regeneración (CARE), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
  4. Claudia Oyanadel: Centro de Biología Celular y Biomedicina (CEBICEM), Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile.
  5. Sofía Espinoza: Centro de Envejecimiento y Regeneración (CARE), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
  6. Claudia Metz: Centro de Envejecimiento y Regeneración (CARE), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
  7. Claudio Retamal: Centro de Biología Celular y Biomedicina (CEBICEM), Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile.
  8. Loreto Massardo: Centro de Biología Celular y Biomedicina (CEBICEM), Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile.
  9. Cheril Tapia-Rojas: Centro de Biología Celular y Biomedicina (CEBICEM), Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile.
  10. Nibaldo C Inestrosa: Centro de Envejecimiento y Regeneración (CARE), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
  11. Andrea Soza: Centro de Envejecimiento y Regeneración (CARE), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile. andrea.soza@uss.cl.
  12. Alfonso González: Centro de Envejecimiento y Regeneración (CARE), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile. agonzara@uss.cl. ORCID

Abstract

Galectin-8 (Gal-8) is a glycan-binding protein that modulates a variety of cellular processes interacting with cell surface glycoproteins. Neutralizing anti-Gal-8 antibodies that block Gal-8 functions have been described in autoimmune and inflammatory disorders, likely playing pathogenic roles. In the brain, Gal-8 is highly expressed in the choroid plexus and accordingly has been detected in human cerebrospinal fluid. It protects against central nervous system autoimmune damage through its immune-suppressive potential. Whether Gal-8 plays a direct role upon neurons remains unknown. Here, we show that Gal-8 protects hippocampal neurons in primary culture against damaging conditions such as nutrient deprivation, glutamate-induced excitotoxicity, hydrogen peroxide (HO)-induced oxidative stress, and β-amyloid oligomers (Aβo). This protective action is manifested even after 2 h of exposure to the harmful condition. Pull-down assays demonstrate binding of Gal-8 to selected β1-integrins, including α3 and α5β1. Furthermore, Gal-8 activates β1-integrins, ERK1/2, and PI3K/AKT signaling pathways that mediate neuroprotection. Hippocampal neurons in primary culture produce and secrete Gal-8, and their survival decreases upon incubation with human function-blocking Gal-8 autoantibodies obtained from lupus patients. Despite the low levels of Gal-8 expression detected by real-time PCR in hippocampus, compared with other brain regions, the complete lack of Gal-8 in Gal-8 KO mice determines higher levels of apoptosis upon HO stereotaxic injection in this region. Therefore, endogenous Gal-8 likely contributes to generate a neuroprotective environment in the brain, which might be eventually counteracted by human function-blocking autoantibodies.

Keywords

References

  1. Nat Med. 2001 Mar;7(3):324-30 [PMID: 11231631]
  2. Brain Res. 2005 Aug 23;1054(1):1-8 [PMID: 16054115]
  3. Autoimmun Rev. 2017 Jun;16(6):612-619 [PMID: 28428121]
  4. Biochem Biophys Res Commun. 2005 Apr 1;329(1):305-11 [PMID: 15721307]
  5. Lupus. 2009 May;18(6):539-46 [PMID: 19395456]
  6. J Biol Chem. 2001 Aug 17;276(33):31285-95 [PMID: 11371555]
  7. J Neurosci. 1984 Feb;4(2):394-410 [PMID: 6699682]
  8. FEBS Lett. 2010 Aug 20;584(16):3601-8 [PMID: 20655311]
  9. Neural Regen Res. 2013 Feb 5;8(4):376-82 [PMID: 25206678]
  10. Pflugers Arch. 2009 Sep;458(5):937-52 [PMID: 19430810]
  11. Cell Death Dis. 2013 Jun 27;4:e689 [PMID: 23807218]
  12. Mol Cell Neurosci. 2005 Mar;28(3):588-98 [PMID: 15737747]
  13. Rev Med Chil. 2006 Feb;134(2):159-66 [PMID: 16554922]
  14. Nat Med. 2004 Jul;10 Suppl:S18-25 [PMID: 15298006]
  15. Cell Mol Life Sci. 2007 Jul;64(13):1679-700 [PMID: 17497244]
  16. J Neurosci Res. 1998 Dec 1;54(5):639-54 [PMID: 9843155]
  17. Front Mol Neurosci. 2017 Jul 11;10:217 [PMID: 28744198]
  18. Histol Histopathol. 2012 Apr;27(4):397-416 [PMID: 22374719]
  19. Dev Neurobiol. 2011 Nov;71(11):1054-72 [PMID: 21761574]
  20. Mol Psychiatry. 2003 Feb;8(2):195-208 [PMID: 12610652]
  21. Sci Transl Med. 2012 Aug 15;4(147):147ra111 [PMID: 22896675]
  22. J Neurosci. 1999 Nov 15;19(22):9964-74 [PMID: 10559404]
  23. J Neuropathol Exp Neurol. 2004 Mar;63(3):255-61 [PMID: 15055449]
  24. J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [PMID: 6606682]
  25. Mol Syst Biol. 2009;5:246 [PMID: 19225459]
  26. J Biol Chem. 1997 Oct 31;272(44):27665-70 [PMID: 9346906]
  27. Nature. 2017 Jan 19;541(7637):412-416 [PMID: 28077878]
  28. Front Neurosci. 2017 Dec 01;11:672 [PMID: 29249935]
  29. PLoS One. 2017 Jun 26;12(6):e0177472 [PMID: 28650992]
  30. Science. 1998 Nov 13;282(5392):1318-21 [PMID: 9812896]
  31. Nat Biotechnol. 2007 Jan;25(1):91-9 [PMID: 17187059]
  32. Immunity. 2012 Aug 24;37(2):249-63 [PMID: 22884314]
  33. Adv Neurobiol. 2014;9:517-42 [PMID: 25151395]
  34. J Clin Rheumatol. 2009 Jun;15(4):203-10 [PMID: 19502907]
  35. Nat Biotechnol. 2003 Jun;21(6):652-9 [PMID: 12730667]
  36. J Neurochem. 2018 Feb;144(4):443-465 [PMID: 29240990]
  37. Arthritis Rheumatol. 2015 Jun;67(6):1598-610 [PMID: 25709106]
  38. Pathog Dis. 2017 Jul 31;75(5): [PMID: 28449072]
  39. Nat Rev Neurosci. 2004 Sep;5(9):686-700 [PMID: 15322527]
  40. J Neurosci. 2014 Feb 5;34(6):2191-202 [PMID: 24501359]
  41. Glycobiology. 2003 Nov;13(11):755-63 [PMID: 12881409]
  42. J Biol Chem. 2016 Sep 2;291(36):19092-107 [PMID: 27402827]
  43. Histol Histopathol. 2014 Sep;29(9):1093-105 [PMID: 24696431]
  44. Eur J Pharmacol. 2010 May 10;633(1-3):1-9 [PMID: 20149790]
  45. JCI Insight. 2019 Jan 10;4(1):null [PMID: 30626758]
  46. Neuropathol Appl Neurobiol. 2011 Oct;37(6):654-71 [PMID: 21501208]
  47. Nature. 2012 Jan 15;482(7385):414-8 [PMID: 22246324]
  48. Biochemistry. 2011 Sep 27;50(38):8127-37 [PMID: 21838267]
  49. Cell Signal. 2008 Jan;20(1):21-30 [PMID: 17716864]
  50. J Neurosci. 2004 Feb 25;24(8):1873-80 [PMID: 14985427]
  51. Exp Cell Res. 2001 Feb 1;263(1):65-76 [PMID: 11161706]
  52. Eur J Biochem. 2004 Jun;271(11):2050-5 [PMID: 15153093]
  53. Biochim Biophys Acta. 2016 Mar;1862(3):442-51 [PMID: 26499397]
  54. Front Mol Neurosci. 2016 Dec 16;9:139 [PMID: 28018170]
  55. J Neurochem. 2003 Feb;84(4):878-90 [PMID: 12562530]
  56. J Neurochem. 2004 Mar;88(5):1240-52 [PMID: 15009680]
  57. J Neurosci. 2007 May 16;27(20):5313-25 [PMID: 17507554]
  58. J Neurochem. 2001 Mar;76(5):1485-96 [PMID: 11238733]
  59. Biol Res. 2013;46(3):275-80 [PMID: 24346075]
  60. J Cell Sci. 2000 Jul;113 ( Pt 13):2385-97 [PMID: 10852818]
  61. Front Cell Neurosci. 2013 Jun 25;7:97 [PMID: 23805073]
  62. J Biol Chem. 2018 Feb 16;293(7):2438-2451 [PMID: 29282296]
  63. Mol Neurobiol. 2018 May;55(5):4473-4491 [PMID: 28674997]
  64. J Biol Chem. 2009 May 8;284(19):12670-9 [PMID: 19276072]
  65. Cell. 1994 Jun 17;77(6):817-27 [PMID: 8004671]
  66. Brain Res. 2008 Mar 10;1198:1-15 [PMID: 18261717]
  67. J Neurochem. 2013 Apr;125(1):49-62 [PMID: 23311731]
  68. Adv Exp Med Biol. 2002;513:41-86 [PMID: 12575817]
  69. Mol Cell. 2018 Apr 5;70(1):120-135.e8 [PMID: 29625033]
  70. Front Mol Neurosci. 2018 May 14;11:158 [PMID: 29867350]
  71. Lancet Neurol. 2016 Jul;15(8):869-881 [PMID: 27180033]
  72. PLoS One. 2015 Jun 30;10(6):e0130772 [PMID: 26126176]
  73. Immunity. 2012 Mar 23;36(3):322-35 [PMID: 22444630]
  74. Brain Res. 2007 Apr 27;1143:11-21 [PMID: 17336275]
  75. Exp Cell Res. 2006 Feb 15;312(4):374-86 [PMID: 16368432]
  76. Biochem J. 2008 Nov 1;415(3):333-44 [PMID: 18842113]
  77. Fluids Barriers CNS. 2014 May 01;11:10 [PMID: 24817998]
  78. Nat Rev Rheumatol. 2019 Mar;15(3):137-152 [PMID: 30659245]
  79. Semin Cell Dev Biol. 2018 Nov;83:42-50 [PMID: 29501720]
  80. Exp Neurol. 2007 Oct;207(2):302-13 [PMID: 17706645]
  81. Exp Neurol. 2007 Sep;207(1):13-22 [PMID: 17599836]
  82. Mol Biol Cell. 2018 Mar 1;29(5):557-574 [PMID: 29298841]
  83. Prog Neurobiol. 2014 Apr;115:157-88 [PMID: 24361499]
  84. J Cell Sci. 2015 Jul 1;128(13):2213-9 [PMID: 26092931]
  85. Nat Neurosci. 2007 Jun;10(6):712-9 [PMID: 17486104]
  86. Arthritis Rheumatol. 2015 Jan;67(1):204-14 [PMID: 25302407]
  87. Physiol Rev. 2018 Apr 1;98(2):813-880 [PMID: 29488822]
  88. Curr Opin Neurol. 2018 Jun;31(3):300-305 [PMID: 29461425]
  89. Front Immunol. 2017 Sep 11;8:1101 [PMID: 28955334]
  90. J Neurosci. 2011 May 25;31(21):7791-800 [PMID: 21613492]
  91. N Engl J Med. 2008 Sep 25;359(13):1317-29 [PMID: 18815396]
  92. Mol Biol Cell. 2003 Jul;14(7):2665-76 [PMID: 12857855]
  93. Immunol Cell Biol. 2016 Feb;94(2):213-9 [PMID: 26282995]
  94. Eur J Neurosci. 2006 Dec;24(11):3017-25 [PMID: 17156363]

Grants

  1. Programa de Apoyo de Centros con Financiamiento Basal AFB 170005/Comisión Nacional de Investigación Científica y Tecnológica
  2. Programa de Apoyo a Centros con Financiamiento Basal AFB 170005/Comisión Nacional de Investigación Científica y Tecnológica
  3. Programa de Apoyo a Centros con Financiamiento Basal AFB 170005/Comisión Nacional de Investigación Científica y Tecnológica
  4. Programa de Apoyo a Centros con Financiamiento Basal AFB 170005/Comisión Nacional de Investigación Científica y Tecnológica
  5. Programa de Apoyo a Centros con Financiamiento Basal AFB 170005/Comisión Nacional de Investigación Científica y Tecnológica
  6. Programa de Apoyo a Centros con Financiamiento Basal AFB 170005/Comisión Nacional de Investigación Científica y Tecnológica
  7. Programa de Apoyo a Centros con Financiamiento Basal AFB 170005/Comisión Nacional de Investigación Científica y Tecnológica
  8. Programa de Apoyo a Centros con Financiamiento Basal AFB 170005/Comisión Nacional de Investigación Científica y Tecnológica
  9. PhD Fellowship/Comisión Nacional de Investigación Científica y Tecnológica
  10. PhD Fellowship/Comisión Nacional de Investigación Científica y Tecnológica
  11. PAI 77170091/Comisión Nacional de Investigación Científica y Tecnológica
  12. PhD fellowship Nº 3120061/Fondo de Fomento al Desarrollo Científico y Tecnológico
  13. 11170546/Fondo de Fomento al Desarrollo Científico y Tecnológico
  14. 1160513/Fondo de Fomento al Desarrollo Científico y Tecnológico
  15. 1131122/Fondo de Fomento al Desarrollo Científico y Tecnológico
  16. For Women In Science International Fellowship/United Nations Educational, Scientific and Cultural Organization (FR); Fondation L'Oreal
  17. AFB 170004/Programa de Apoyo a Centros con Financiamiento Basal

MeSH Term

Animals
Antibodies, Neutralizing
Apoptosis
Autoantibodies
Brain
Cell Survival
Extracellular Signal-Regulated MAP Kinases
Galectins
Hippocampus
Humans
Hydrogen Peroxide
Integrin beta1
Neurons
Neuroprotection
Protein Binding
Proto-Oncogene Proteins c-akt
Rats, Sprague-Dawley
Signal Transduction

Chemicals

Antibodies, Neutralizing
Autoantibodies
Galectins
Integrin beta1
LGALS8 protein, human
Hydrogen Peroxide
Proto-Oncogene Proteins c-akt
Extracellular Signal-Regulated MAP Kinases

Word Cloud

Created with Highcharts 10.0.0Gal-8neuronsbrainhumanuponautoimmunelikelydetectedprotectsprimarycultureHOβ1-integrinsERK1/2PI3K/AKTHippocampalfunction-blockingautoantibodieslevelsGalectin-8glycan-bindingproteinmodulatesvarietycellularprocessesinteractingcellsurfaceglycoproteinsNeutralizinganti-Gal-8antibodiesblockfunctionsdescribedinflammatorydisordersplayingpathogenicroleshighlyexpressedchoroidplexusaccordinglycerebrospinalfluidcentralnervoussystemdamageimmune-suppressivepotentialWhetherplaysdirectroleremainsunknownshowhippocampaldamagingconditionsnutrientdeprivationglutamate-inducedexcitotoxicityhydrogenperoxide-inducedoxidativestressβ-amyloidoligomersAβoprotectiveactionmanifestedeven2 hexposureharmfulconditionPull-downassaysdemonstratebindingselectedincludingα3α5β1FurthermoreactivatessignalingpathwaysmediateneuroprotectionproducesecretesurvivaldecreasesincubationobtainedlupuspatientsDespitelowexpressionreal-timePCRhippocampuscomparedregionscompletelackKOmicedetermineshigherapoptosisstereotaxicinjectionregionThereforeendogenouscontributesgenerateneuroprotectiveenvironmentmighteventuallycounteractedGALECTIN-8NeuroprotectiveFactorBrainCanNeutralizedHumanAutoantibodiesGalectinsIntegrinsNeuroprotection

Similar Articles

Cited By